[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497241":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":58,"centralContacts":62,"locations":68,"responsibleParty":82,"collaborators":85,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":66,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":66,"maxAge":96,"enrollmentInfo":97,"targetDuration":66,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":66,"overallStatus":71,"whyStopped":66,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Hong Kong Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Quadruple immunotherapy",[13,14,15,16,17,18],"Biological: Natural killer cell","Drug: Dinutuximab beta","Drug: Interleukin-2","Drug: Granulocyte-Macrophage Colony-Stimulating Factor","Drug: Spironolactone","Drug: Naxitamab",[20,27,34,40,46,52],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Natural killer cell","Natural killer cells isolated from HLA-haploidentical relative donor",[9],[26],"NK cell",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Dinutuximab beta","Dinutuximab beta iv for 5 days",[9],[33],"Ch14.18",{"type":28,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Interleukin-2","Interleukin-2 sc alternate day for 6 doses",[9],[39],"Aldesleukin",{"type":28,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Granulocyte-Macrophage Colony-Stimulating Factor","Granulocyte-macrophage colony-stimulating factor sc daily till ANC \\>2,000\u002Fmm3",[9],[45],"Sargramostim",{"type":28,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Spironolactone","Spironolactone po three time daily",[9],[51],"Aldactone",{"type":28,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Naxitamab","Naxitamab iv for 4 days (as alternative for dinutuximab)",[9],[57],"hu3F8",[59],{"name":60,"affiliation":5,"role":61},"Daniel Cheuk","PRINCIPAL_INVESTIGATOR",[63],{"name":60,"role":64,"phone":65,"phoneExt":66,"email":67},"CONTACT","852-35136049",null,"cheukkld@gmail.com",[69],{"facility":70,"status":71,"city":72,"state":66,"zip":66,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Hong Kong Children's Hospital","RECRUITING","Hong Kong","HK",{"type":75,"coordinates":76},"Point",[77,78],114.17469,22.27832,{"lat":78,"lon":77},[81],{"name":60,"role":64,"phone":65,"phoneExt":66,"email":67},{"type":61,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":66,"oldOrganization":66},"Cheuk Ka Leung Daniel","Consultant",[86],{"name":87,"class":6},"The University of Hong Kong","100497241","phase-2-quadruple-immunotherapy-for-neuroblastoma-100497241",false,"NCT05754684","Quadruple Immunotherapy for Neuroblastoma","Quadruple Immunotherapy for Paediatric Patients With Relapsed or Refractory Neuroblastoma","Inclusion Criteria:\n\n* relapsed or refractory neuroblastoma\n* Adequate organ function: creatinine clearance ≥40 ml\u002Fmin\u002F1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU\u002FL, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air\n* Karnofsky or Lansky performance status score ≥50\n* Has an appropriate HLA-haploidentical NK-cell donor available\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom conventional treatment is deemed more appropriate\n* Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \\\u003C1 month","ALL","18 Years",{"count":98,"type":99},29,"ESTIMATED","INTERVENTIONAL",[102],"PHASE2","This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.",[105],"Neuroblastoma Recurrent","2025-09-08",{"date":108,"type":109},"2025-09-15","ACTUAL",{"date":111,"type":109},"2022-01-01",{"date":113,"type":99},"2025-12-31",{"name":5,"class":6},1]